Recruiting soon

AI Models Performance in Clinical Pathology Diagnostic Workflow

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to evaluate the performance of AI models in the clinical pathology diagnostic workflow by measuring the area under the receiver operating characteristic curve (AUC).

What is being tested

AI model

+ Control

Other
Who is being recruted

From 18 to 100 Years
See all eligibility criteria
How is the trial designed

Other Study

Placebo-Controlled
Interventional
Study Start: March 2026
See protocol details

Summary

Principal SponsorNanfang Hospital, Southern Medical University
Study ContactZhengyu Zhang
Last updated: February 14, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: March 1, 2026

Actual date on which the first participant was enrolled.

This study focuses on how well AI models perform in the clinical pathology diagnostic process. It involves 60 pathologists with different levels of experience and 2,000 patients who need a pathological diagnosis. The goal is to understand how AI can assist in analyzing whole-slide images, potentially improving the accuracy and efficiency of diagnosis. This is important because it could help address current challenges in pathology, such as high workload and complexity of cases. During the study, pathologists use AI models to help them analyze whole-slide images. The main outcome measured is the 'area under the ROC curve (AUC)', which is a measure of how well the AI models can distinguish between different diagnostic outcomes. This helps evaluate the performance of the AI models in assisting the pathologists.

Official TitlePerformance of AI Models in the Clinical Pathology Diagnostic Workflow: A Multicenter, Prospective, Randomized Controlled Trial
Principal SponsorNanfang Hospital, Southern Medical University
Study ContactZhengyu Zhang
Last updated: February 14, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

2060 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Other Study

Some studies explore topics that don't fall into a specific category. These might include innovative research, new technologies, or emerging healthcare areas.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 100 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

Pathologists: Inclusion Criteria: 1. Voluntarily provide written informed consent. 2. Age ≥ 20 years. 3. Have completed at least 1 year of training in pathological diagnosis. Exclusion Criteria: 1. Individuals with reading difficulties or a reading disorder. 2. Unwilling to participate in this study. Patients: Inclusion Criteria: 1. Voluntarily provide written informed consent. 2. Age ≥ 18 years. 3. Have available digital pathology images and relevant clinical information. Exclusion Criteria: 1. Missing data or data quality not meeting the requirements for analysis. 2. Deemed unsuitable for participation by the investigator. 3. Unwilling to participate in this study.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Pathologists in this group are required to use the AI pathology diagnostic model to assist their diagnoses. The AI pathology model will provide a predicted result for each case.

Group II

Placebo
In this group, pathologists will independently diagnose each case based on their own clinical experience, and will record both their time to diagnosis and their diagnostic confidence.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 3 locations

Suspended

The First Hospital Affiliated to AMU SOUTHWEST HOSPITAL

Chongqing, ChinaOpen The First Hospital Affiliated to AMU SOUTHWEST HOSPITAL in Google Maps
Suspended

Nanfang Hospital, Southern Medical University

Guangzhou, China
Suspended

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, China
Recruiting soon3 Study Centers